C12Y 304/21053
Endopeptidase la
Official title: Endopeptidase La (3.4.21.53)
C12Y304/21053 (Endopeptidase la) appears on 2 US grants and 6 published applications in this corpus.
Search patents in C12Y- Granted patents
- 2
- Published applications
- 6
- Assignees
- 5
- Inventors
- 16
- Latest grant
- 6 Jun 2023
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2013 | 0 | 1 |
| 2014 | 0 | 0 |
| 2015 | 1 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 0 |
| 2021 | 0 | 1 |
| 2022 | 0 | 0 |
| 2023 | 1 | 1 |
| 2024 | 0 | 0 |
| 2025 | 0 | 2 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Engineered Microbes Comprising Tumor Neoantigen Vectors for Cancer Immunotherapy18 Jun 2026US 2026/0166133 A1The Trustees of Columbia University in the City of New York
- Lon protease, alpha-hemolysin, ck1-alpha-1; c-myb inhibitor or a cebp-delta inhibitor as therapeutics25 Dec 2025US 2025/0388889 A1Linnane Pharma AB
- Custom bacterial strain for recombinant protein production13 Feb 2025US 2025/0051736 A1ModernaTX, Inc.
- Lon protease, alpha-hemolysin, ck1-alpha-1; c-myb inhibitor or a cebp-delta inhibitor as therapeutics23 Feb 2023US 2023/0055209 A1Linnane Pharma AB
- Defined therapeutic microbiota and methods of use thereof11 Mar 2021US 2021/0069264 A1The Brigham and Women S Hospital, Inc.
Most cited
By later US patents